United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Pfizer Inc's (NYSE: PFE) COVID-19 vaccine that it developed in collaboration with German BioNTech is expected to receive full FDA approval on Monday – a few weeks ahead of the announced deadline of September 6th. The drug regulatory authority refrained from commenting any further on the news first reported by the New York Times.

Pfizer expecting full FDA approval for its COVID-19 vaccine today

What does the FDA approval of Pfizer-BioNTech's coronavirus vaccine mean for the stock market today. The post Pfizer-BioNTech Gains FDA Approval, 7 Things To Know Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Pfizer-BioNTech Gains FDA Approval, 7 Things To Know Right Now

The FDA has approved Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine, making it the first to receive full FDA approval. The vaccine will now be marketed as 'Comirnaty' to prevent COVID-19 infection in individuals 16 years and older.

Pfizer-BioNTech's COVID-19 Vaccine Becomes First To Receive Full FDA Approval

The shift from emergency use to full approval for the Pfizer-BioNTech shot could spur more people to get vaccinated and support more mandates.

The FDA just fully approved Pfizer's COVID-19 vaccine in a move that could lead to more vaccinations

U.S. officials hope full approval will boost trust in the jab.

FDA Approves Pfizer Coronavirus Vaccine, Report Says

The FDA's approval of the Pfizer and BioNTech Covid shot will likely spur more businesses to adopt vaccine mandates for workers.

FDA grants full approval to Pfizer-BioNTech's Covid shot, clearing path to more vaccine mandates

Trillium Therapeutics

Pfizer had originally invested $25 million in Trillium in September of last year, as part of its breakthrough growth initiative.

Trillium Therapeutics soars 200% after Pfizer inks deal to buy cancer-drug company for $2.3 billion

Pfizer Inc (NYSE: PFE) has agreed to acquire Trillium Therapeutics Inc (NASDAQ: TRIL) for $18.50 per share, equivalent to an implied equity value of $2.26 billion. The offer price represents a 118% premium to the 60-day weighted average price for Trillium.

Pfizer Beefs Up Blood Cancer Pipeline With Trillium Acquisition: See Highlights

The company's vaccine received emergency use authorization in December. Since then, more than 204 million doses of the vaccine have been administered in the U.S. alone.

Full FDA Approval for Pfizer Vaccine Could Bring More Mandates

The European Commission (EC) has approved Pfizer Inc's (NYSE: PFE) Xeljanz (tofacitinib) for active polyarticular juvenile idiopathic arthritis (JIA) and juvenile psoriatic arthritis (PsA).  The approval covers two years of age and older patients who did not respond to previous therapy with disease-modifying antirheumatic drugs (DMARDs).

Pfizer's Arthritis Drug Wins European Approval In Pediatric & Adult Patients

AT&T

Economic reports are showing even more signs of deterioration and, unfortunately, this has led to significant downside revisions in the U.S. consumer outlook.

Consumer Collapse Ahead? Buy These 2 Dividend Stocks

Pfizer's $2.26B Trillium deal will target drugs for blood cancers, such as leukemia, multiple myeloma and lymphoma, according to the companies.

Trillium Therapeutics shares soar on Pfizer's $2.26B deal

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) shares are trading higher following reports indicating the FDA is expected to fully approve Pfizer and BioNTech's COVID-19 vaccine this week. The two-dose shot was first cleared in December by the agency on an emergency use basis for people 16 years and older.

Why Pfizer And BioNTech Shares Are Trading Higher Today

Shares of Trillium Therapeutics Inc. TRIL, +3.92% nearly tripled in premarket trading Monday, skyrocketing 189.3%, after the immuno-oncology company announced an agreement to be acquired by Pfizer Inc. PFE, -0.16% in a cash deal valued $2.26 billion. Under terms of the agreement, Pfizer will pay $18.50 for each Trillium share it doesn't already own, which is 203.8% above Friday's closing price of $6.09.

Trillium Therapeutics' stock nearly triples after buyout deal with Pfizer valued at $2.26 billion

Pfizer Inc said on Monday it would buy shares of Trillium Therapeutics Inc that it does not already own in a deal that values the cancer drugs maker at $2.26 billion.

Pfizer to buy Trillium Therapeutics in $2.26 billion deal

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium not already owned by Pfizer for an implied equity value of $2.26 billi

Pfizer to Acquire Trillium Therapeutics Inc.

A third shot of the Pfizer vaccine dramatically reduced the risk of Covid-19 infection and subsequent hospitalization among people who are older than 60.

Pfizer Booster Significantly Lowers Risk Of Covid-19 Infection Among Elderly, Israeli Gov't Finds

The mRNA vaccine developed by Pfizer, Inc. (NYSE: PFE) and its German partner BioNTech SE against the novel coronavirus was the first to receive emergency use authorization from the U.S. Food and Drug Administration. The combo's vaccine could also end up being the first to receive full approval.

Pfizer On The Cusp of Getting Full Approval For Its COVID-19 Vaccine: What You Need to Know

AbbVie

Johnson & Johnson

These pharmaceutical giants offer strong, dependable dividends and the size to weather the market's ups and downs.

3 Boring Healthcare Stocks Everyone Should Own

Hint: It's not the anticipated FDA approval of Pfizer and BioNTech's COVID vaccine.

Here's How This Vaccine Approval From the FDA Benefits Pfizer

Both stocks have plenty to offer investors.

Better Dividend Stock: Johnson & Johnson or Pfizer?

The shot is currently being given in the US under an emergency use authorization.

FDA set to give Pfizer's COVID-19 vaccine full approval next week, report says

Pfizer Inc. PFE, -0.16% and U.S. shares of BioNTech SE BNTX, +5.08% rose in the extended session Friday following a report that the drug makers will likely get full Food and Drug Administration approval for their COVID-19 vaccine sometime next week. Pfizer shares rose more than 2% after hours, following a 0.2% decline to close at $48.72, and BioNTech's ADRs rallied more than 5%, following a 5.1% gain to close at $348.68.

Pfizer, BioNTech stocks rise on report FDA could fully approve COVID-19 vaccine

Pfizer Inc. PFE, +2.71% and U.S. shares of BioNTech SE BNTX, +8.28% rose in the extended session Friday following reports that the drug makers will likely get full Food and Drug Administration approval for their COVID-19 vaccine sometime next week.

Pfizer and BioNTech shares rise on report FDA could fully approve COVID-19 vaccine next week

Approval for Pfizer's vaccine — which the New York Times and Politico say is on track for next week — could boost vaccination rates as the pandemic resurges, some experts believe.

News for Pfizer Stock (PFE)